[go: up one dir, main page]

BRPI0508397A - derivado de tiazol ou um sal farmaceuticamente aceitável do mesmo, inibidor de alk5, estimulador de proliferação de folìculo capilar, e, estimulador do crescimento capilar ou um agente de crescimento capilar - Google Patents

derivado de tiazol ou um sal farmaceuticamente aceitável do mesmo, inibidor de alk5, estimulador de proliferação de folìculo capilar, e, estimulador do crescimento capilar ou um agente de crescimento capilar

Info

Publication number
BRPI0508397A
BRPI0508397A BRPI0508397-4A BRPI0508397A BRPI0508397A BR PI0508397 A BRPI0508397 A BR PI0508397A BR PI0508397 A BRPI0508397 A BR PI0508397A BR PI0508397 A BRPI0508397 A BR PI0508397A
Authority
BR
Brazil
Prior art keywords
derivative
hair growth
hair
enhancer
pharmaceutically acceptable
Prior art date
Application number
BRPI0508397-4A
Other languages
English (en)
Inventor
Masakazu Sato
Yuko Matsunaga
Hajime Asanuma
Hideaki Amada
Takeshi Koami
Tetsuo Takayama
Tetsuya Yabuuchi
Fumiyasu Shiozawa
Hironori Katakai
Hiroki Umemiya
Akiko Ikeda
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of BRPI0508397A publication Critical patent/BRPI0508397A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

DERIVADO DE TIAZOL OU UM SAL FARMACEUTICAMENTE ACEITáVEL DO MESMO, INIBIDOR DE ALK5, ESTIMULADOR DE PROLIFERAçãO DE FOLICULO CAPILAR, E, ESTIMULADOR DO CRESCIMENTO CAPILAR OU UM AGENTE DE CRESCIMENTO CAPILAR Um derivado de tiazolilimidazol representado pela fórmula (em que X¬ 1¬ e X¬ 2¬ são diferentes e cada um representa enxofre ou carbono; R~1~ representa fenila, fenila substituido, fenila substituido com um anel heteroaromático, piridila, ou piridila fundido com um anel heteroaromático; R~ 2~ representa hidrogênio, halogênio alquila C~ |-6~, alquila C~ 1-6~ substituido com de um a cinco átomos de halogênio, alcóxi C~ 1-6¬, alcanoila C~ 1-6~, ou hidroxialquila C~ 1-5~; e A representa um grupo representado pela fórmula a seguir) ou um sal farmaceuticamente aceitável do derivado; e um inibição de ALK 5, agente terapêutico para alopecia, ou restaurador de cabelo, sendo que cada um contém o derivado ou sal como um ingrediente ativo. O derivado ou sal é uma substância que inibe ALK 5, que é um receptor tipo I de TGF-B, A preparação para crescimento de cabelos ou restaurador de cabelos baseia-se numa função inédita.
BRPI0508397-4A 2004-03-05 2005-03-04 derivado de tiazol ou um sal farmaceuticamente aceitável do mesmo, inibidor de alk5, estimulador de proliferação de folìculo capilar, e, estimulador do crescimento capilar ou um agente de crescimento capilar BRPI0508397A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004062321 2004-03-05
JP2004344307 2004-11-29
PCT/JP2005/003755 WO2005085241A1 (ja) 2004-03-05 2005-03-04 チアゾール誘導体

Publications (1)

Publication Number Publication Date
BRPI0508397A true BRPI0508397A (pt) 2007-08-07

Family

ID=34921704

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508397-4A BRPI0508397A (pt) 2004-03-05 2005-03-04 derivado de tiazol ou um sal farmaceuticamente aceitável do mesmo, inibidor de alk5, estimulador de proliferação de folìculo capilar, e, estimulador do crescimento capilar ou um agente de crescimento capilar

Country Status (13)

Country Link
US (2) US7678810B2 (pt)
EP (1) EP1721905A4 (pt)
JP (1) JP4853284B2 (pt)
KR (1) KR101150077B1 (pt)
AU (1) AU2005219737B2 (pt)
BR (1) BRPI0508397A (pt)
CA (1) CA2556944C (pt)
MY (1) MY146532A (pt)
NO (1) NO20064366L (pt)
NZ (1) NZ549003A (pt)
RU (1) RU2367661C2 (pt)
WO (1) WO2005085241A1 (pt)
ZA (1) ZA200606734B (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ549003A (en) * 2004-03-05 2009-07-31 Taisho Pharmaceutical Co Ltd Thiazole derivative as an ALK5 inhibitor
AU2006335108B2 (en) * 2005-12-30 2011-04-07 Merck Sharp & Dohme Corp. CETP inhibitors
US7649098B2 (en) * 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
JP2010501567A (ja) 2006-08-24 2010-01-21 ノバルティス アクチエンゲゼルシャフト 代謝系、心血管系および他の障害の処置のためのステアロイル−ＣｏＡ不飽和化酵素（ＳＣＤ）阻害剤としての２−（ピラジン−２−イル）−チアゾールおよび２−（１Ｈ−ピラゾール−３−イル）チアゾール誘導体ならびに関連化合物
JP5351025B2 (ja) 2006-09-22 2013-11-27 ノバルティス アーゲー ヘテロ環式有機化合物
KR20090091337A (ko) 2006-12-20 2009-08-27 노파르티스 아게 Ｓｃｄ 억제제로서의 ２-치환 ５-원 헤테로사이클
TW200920355A (en) * 2007-09-06 2009-05-16 Lexicon Pharmaceuticals Inc Compositions and methods for treating immunological and inflammatory diseases and disorders
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
US8129394B2 (en) * 2008-03-21 2012-03-06 Novartis Ag Heteroaryl-substituted imidazole compounds and uses thereof
WO2010126022A1 (ja) * 2009-04-28 2010-11-04 大正製薬株式会社 イミダゾール誘導体
US8822464B2 (en) 2011-11-28 2014-09-02 Boehringer Ingelheim International Gmbh N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8741892B2 (en) 2011-12-05 2014-06-03 Boehringer Ingelheim International Gmbh Compounds
US8796467B2 (en) 2011-12-13 2014-08-05 Boehringer Ingelheim International Gmbh Compounds
US8846948B2 (en) 2011-12-13 2014-09-30 Boehringer Ingelheim International Gmbh Compounds
US8883789B2 (en) 2011-12-14 2014-11-11 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8937176B2 (en) 2011-12-14 2015-01-20 Boehringer Ingelheim International Gmbh Compounds
US8716277B2 (en) 2011-12-14 2014-05-06 Boehringer Ingelheim International Gmbh Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity
US8889677B2 (en) 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
WO2013181326A1 (en) 2012-05-30 2013-12-05 Cornell University Generation of functional and durable endothelial cells from human amniotic fluid-derived cells
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
JP6529486B2 (ja) 2013-06-05 2019-06-12 バイオタイム インク．Ｂｉｏｔｉｍｅ Ｉｎｃ． 哺乳動物種における誘導組織再生のための組成物および方法
US11078462B2 (en) 2014-02-18 2021-08-03 ReCyte Therapeutics, Inc. Perivascular stromal cells from primate pluripotent stem cells
US10240127B2 (en) 2014-07-03 2019-03-26 ReCyte Therapeutics, Inc. Exosomes from clonal progenitor cells
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
CN107108467B (zh) * 2014-12-24 2022-08-19 北京生命科学研究所 细胞坏死抑制剂
WO2017100313A1 (en) 2015-12-07 2017-06-15 Biotime, Inc. Methods for the re-derivation of diverse pluripotent stem cell-derive brown fat cells
US11583593B2 (en) 2016-01-14 2023-02-21 Synthis Therapeutics, Inc. Antibody-ALK5 inhibitor conjugates and their uses
KR102434226B1 (ko) 2016-06-30 2022-08-19 한미약품 주식회사 Alk5 억제제로서의 신규 피라졸 유도체 및 이의 용도
CN109689654A (zh) 2016-07-11 2019-04-26 拜耳医药股份有限公司 7-取代的1-吡啶基-萘啶-3-甲酰胺类及其用途
EP3515446B1 (en) 2016-09-19 2023-12-20 Novartis AG Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
JP2020512400A (ja) * 2017-03-23 2020-04-23 クラヴィウス ファーマシューティカルズ，エルエルシー ＴＧＦβの阻害のための三置換イミダゾールおよび治療方法
CN110494166B (zh) 2017-05-02 2022-11-08 诺华股份有限公司 组合疗法
GB201718285D0 (en) * 2017-11-03 2017-12-20 Discuva Ltd Antibacterial Compounds
KR102881316B1 (ko) 2019-05-13 2025-11-05 노파르티스 아게 암 치료를 위한 raf 억제제로서의 n-(3-(2-(2-하이드록시에톡시)-6-모르폴리노피리딘-4-일)-4-메틸페닐)-2 (트리플루오로메틸)이소니코틴아미드의 새로운 결정질 형태
KR20230098211A (ko) 2020-10-30 2023-07-03 닛산 가가쿠 가부시키가이샤 지질펩티드와 자당에스테르를 포함하는 조성물
CN120418231A (zh) * 2022-12-30 2025-08-01 阿勒泰治疗公司 2-取代噻唑和苯并噻唑组合物和作为dux4抑制剂的方法
CN116891472A (zh) * 2023-07-13 2023-10-17 延边大学 一种含咪唑结构的酰胺类衍生物及其制备方法和应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH032540A (ja) * 1989-05-30 1991-01-08 Shimadzu Corp 漏れ試験方法とパッケージ形電子ディバイス
US5338856A (en) * 1992-08-17 1994-08-16 Dowelanco 3,4-N,trisubstituted-4,5-dihydro-1H-pyrazole-1-carboxamides and their use as insecticides
JP3714633B2 (ja) 1993-08-24 2005-11-09 塩野義製薬株式会社 ２−アミノアゾール誘導体
US5620999A (en) 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
JPH08157363A (ja) * 1994-12-02 1996-06-18 Japan Energy Corp 制癌剤
IL133766A0 (en) 1997-06-30 2001-04-30 Ortho Mcneil Pharm Inc 2-substituted imidazoles useful in the treatment of inflammatory diseases
OA12189A (en) * 1998-03-10 2006-05-09 Smithkline Beecham Corp Vitronectin receptor antagonists.
WO2000061576A1 (en) 1999-04-09 2000-10-19 Smithkline Beecham Corporation Triarylimidazoles
MXPA01010675A (es) * 1999-04-23 2002-06-04 Takeda Chemical Industries Ltd Compuestos de 5-piridil-1, 3-azol, proceso para su produccion y uso de los mismos.
JP4815083B2 (ja) * 1999-08-31 2011-11-16 メルク・シャープ・エンド・ドーム・コーポレイション 複素環化合物およびそれの使用方法
US6956049B1 (en) * 1999-08-31 2005-10-18 Merck & Co., Inc. Methods of modulating processes mediated by excitatory amino acid receptors
EG24179A (en) * 1999-09-07 2008-09-28 Smithkline Beecham Corp Vitronectin receptor antagonists
JP2001163861A (ja) * 1999-12-07 2001-06-19 Nippon Soda Co Ltd ジフェニルイミダゾール化合物および農園芸用殺菌剤
PL356172A1 (en) 1999-12-17 2004-06-14 The Procter & Gamble Company N-(1-phenylethyl)-5-phenyl-imidazole-2-amine compounds, their compositions and uses
EP1244678A1 (en) * 1999-12-22 2002-10-02 Merck Frosst Canada Inc. Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b)
AR029803A1 (es) 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
GB0011089D0 (en) 2000-05-08 2000-06-28 Black James Foundation Gastrin and cholecystokinin receptor ligands (11)
GB0027987D0 (en) * 2000-11-16 2001-01-03 Smithkline Beecham Plc Compounds
AU2002225730A1 (en) 2000-11-16 2002-05-27 Smith Kline Beecham Corporation Compounds
WO2002053161A1 (en) * 2000-12-29 2002-07-11 Alteon, Inc. Method for treating fibrotic diseases or other indications
WO2002076494A2 (en) 2001-03-23 2002-10-03 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh USE OF CYTOKINES OF THE TGF-β SUPERFAMILY FOR THE TREATMENT AND DIAGNOSIS OF SKIN RELATED DISORDERS
EP1395831A2 (en) * 2001-04-19 2004-03-10 NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen Method for the relative determination of physicochemical properties
JP3726715B2 (ja) * 2001-06-19 2005-12-14 村田機械株式会社 自動ワインダのテンション制御装置
GB0127433D0 (en) 2001-11-15 2002-01-09 Smithkline Beecham Corp Compounds
CA2474322A1 (en) 2002-01-25 2003-07-31 Kylix Pharmaceuticals B.V. 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2
WO2003080592A1 (en) * 2002-03-27 2003-10-02 Sumitomo Chemical Company, Limited 2-pyrone compounds and use thereof
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
EP1532118A2 (en) 2002-07-05 2005-05-25 Axxima Pharmaceuticals Aktiengesellschaft Imidazole compounds for the treatment of hepatitis c virus infections
JP2005539000A (ja) * 2002-07-31 2005-12-22 スミスクライン・ビーチャム・コーポレイション Ａｌｋ５阻害剤としての２−フェニルピリジン−４−イル誘導体
NZ549003A (en) * 2004-03-05 2009-07-31 Taisho Pharmaceutical Co Ltd Thiazole derivative as an ALK5 inhibitor

Also Published As

Publication number Publication date
US20070154428A1 (en) 2007-07-05
WO2005085241A1 (ja) 2005-09-15
CA2556944A1 (en) 2005-09-15
KR101150077B1 (ko) 2012-06-01
US7678810B2 (en) 2010-03-16
AU2005219737B2 (en) 2009-11-19
JPWO2005085241A1 (ja) 2008-01-17
JP4853284B2 (ja) 2012-01-11
MY146532A (en) 2012-08-15
ZA200606734B (en) 2008-01-08
CA2556944C (en) 2012-10-09
RU2006135111A (ru) 2008-04-10
HK1104543A1 (zh) 2008-01-18
NO20064366L (no) 2006-11-08
NZ549003A (en) 2009-07-31
KR20060124744A (ko) 2006-12-05
US20100216787A1 (en) 2010-08-26
EP1721905A1 (en) 2006-11-15
RU2367661C2 (ru) 2009-09-20
AU2005219737A1 (en) 2005-09-15
EP1721905A4 (en) 2009-11-18

Similar Documents

Publication Publication Date Title
BRPI0508397A (pt) derivado de tiazol ou um sal farmaceuticamente aceitável do mesmo, inibidor de alk5, estimulador de proliferação de folìculo capilar, e, estimulador do crescimento capilar ou um agente de crescimento capilar
BRPI0418082A (pt) antagonista de receptor de adenosina a2a, agente para tratar e/ou prevenir doenças, composto, composição farmacêutica, e, método para tratar e/ou prevenir doenças associadas com receptor de adenosina a2a
BR112013010564A2 (pt) compostos heterocíclicos e usos desses
BR0307409A (pt) Compostos de hidrazida de ácido 2-furanocarboxìlico, composições farmacêuticas contendo os mesmos e uso dos mesmos para preparação de um agente preventivo ou terapêutico
NO324228B1 (no) 4-amino-5-cyano-2-anilino-pyrimidinderivater og deres anvendelse og fremgangsmate for fremstilling, samt farmasoytisk sammensetning
BR112015024078A2 (pt) derivados de benzimidazolona como inibidores de bromodomínio
MEP52408A (en) Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
BRPI0418074B8 (pt) derivado de amida, composição farmacêutica, inibidor da tirosina cinase bcr-abl e agentes terapêuticos
CO6231028A2 (es) Compuestos y composiciones como inhibidores de la proteina quinasa
BRPI0409227B8 (pt) "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)"
AR055592A1 (es) Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace)
EA200800781A1 (ru) АМИДНЫЕ И КАРБАМАТНЫЕ ПРОИЗВОДНЫЕ АЛКИЛЗАМЕЩЕННЫХ N-[4-(4-АМИНО-1Н-ИМИДАЗО[4,5-c]ХИНОЛИН-1-ИЛ)БУТИЛ]МЕТАНСУЛЬФОНАМИДОВ И СПОСОБЫ
UY27370A1 (es) Derivados de benzamida tiazol y composiciones farmacéuticas para inhibir la proliferación de células y métodos para su utilización
BRPI0510095A (pt) tiazol substituìdo e derivados de pirimidina como moduladores de receptores de melanocortina
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
BRPI0312288B8 (pt) derivados de amidas
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
PE20240930A1 (es) Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton
BR0315777A (pt) Uso de derivados de piperazina como antagonistas ccr1
AR036327A1 (es) Compuestos derivados del cromano para uso terapeutico, composicion farmaceutica, uso de estos compuestos para la preparacion de medicamentos para tratar migrana, compuestos relacionados, y procesos para preparar esos compuestos relacionados
BRPI0407841A (pt) inibidores heterocìclicos de quinase
BRPI0416039A (pt) derivados de tiazol e pirazol como inibidores de flt-3 cinase
BRPI0408605A (pt) derivados de 8-perfluoralquil-6,7,8,9-tetrahidropirimido[1,2-a]piri midin-4-ona substituìdos
AR097423A1 (es) Compuestos con actividad plaguicida
BRPI0515991A (pt) derivados de bisariluréia substituìda heterocìclica como inibidores de cinase

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2307 DE 24/03/2015.